Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4281811 | 0.88 | PTGES (0.42) | KDM4EALDH1A1HPGDHSD17B10KMT2A | |
| Hydrochloric Acid SCHEMBL4295442 | 0.88 | KDM4E (0.47) | KDM4EALDH1A1LMNATDP1HPGD | |
| Hydrochloric Acid SCHEMBL4292929 | 0.87 | HPGD (0.38) | HPGDHSD17B10KMT2A | |
| Hydrochloric Acid SCHEMBL4294403 | 0.86 | KMT2A (0.46) | KDM4EALDH1A1HPGDHSD17B10MEN1 | |
| Hydrochloric Acid SCHEMBL4285718 | 0.85 | KDM4E (0.41) | KDM4EALDH1A1HTR1BTDP1MEN1 | |
| SCHEMBL4292712 | 0.85 | DRD3 (0.46) | ALDH1A1HPGDMEN1KMT2ATP53 | |
| SCHEMBL4750156 | 0.85 | DRD3 (0.46) | ALDH1A1HPGDMEN1KMT2ATP53 | |
| Hydrochloric Acid SCHEMBL4289621 | 0.85 | LMNA (0.48) | KDM4EALDH1A1LMNATDP1MEN1 | |
| Hydrochloric Acid SCHEMBL4291908 | 0.82 | HPGD (0.44) | ALDH1A1LMNAHPGDHSD17B10KMT2A | |
| SCHEMBL4281203 | 0.82 | HIF1A (0.43) | ALDH1A1LMNAHPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | KDM4E 760/4885ALDH1A1 388/4885HTR1B 3383/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | KDM4E 760/4885ALDH1A1 388/4885HTR1B 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.